Sonoma Pharmaceu Stock Price, News & Analysis

Sonoma Pharmaceuticals (Nasdaq:SNOA) has announced the launch of its HOCl-based diaper rash product in major U.S. retail channels. The antimicrobial hydrogel, based on their patented Microcyn® technology, is now available in 3,600 Walmart stores, Amazon.com, and various large grocery chains.

This launch marks Sonoma's strategic expansion into the over-the-counter consumer market, offering their stabilized hypochlorous acid (HOCl) technology directly to consumers seeking solutions for diaper rash and skin irritations. The product is being distributed through their U.S.-based distribution partner.

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported its Q1 FY2026 financial results, showing significant growth with total revenue reaching $4.0 million, an 18% increase year-over-year. The company demonstrated strong performance in key markets, with U.S. revenue surging 57% and European revenue growing 14%.

Notable achievements include expanded partnerships with major U.S. retailers, launch of acne products in 1,200+ U.K. stores, and new regulatory approval in Ukraine. Despite revenue growth, the company reported a net loss of $1.2 million and held cash reserves of $3.6 million as of June 30, 2025. Gross profit margin slightly decreased to 36% from 39% in the previous year.

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong financial results for FY2025 and Q4 2025, showing significant improvements across key metrics. Q4 revenue increased 9% to $3.8M, while FY2025 revenue grew 12% to $14.3M. The company reduced its net loss by 27% in Q4 and 29% for the full year. EBITDA loss improved substantially, down 59% in Q4 and 17% for FY2025. Gross profit margins improved to 41% in Q4 2025 from 32% in Q4 2024. Notable achievements include early compliance with EU Medical Device Regulation, MHRA registration in the UK, and expanded distribution networks. The company launched acne products in 1,200+ UK stores and received regulatory approval in Ukraine. Operating expenses decreased by 13% in Q4 and 3% for the full year, reflecting successful cost containment efforts. As of March 31, 2025, cash position stood at $5.4M.

Sonoma Pharmaceuticals (NASDAQ:SNOA) has announced the successful registration of its hypochlorous acid-based acne products with the UK's Medicines & Healthcare products Regulatory Agency (MHRA). The company will launch its products through a major UK pharmacy chain, reaching over 1,200 stores nationwide.

The product line features an acne toner and balancing serum, which will be marketed under the retailer's private label brand. These products are based on Sonoma's patented Microcyn technology, utilizing stabilized hypochlorous acid (HOCl). The formulation offers a natural alternative to traditional acne treatments containing alcohol and benzoyl peroxide.

Sonoma Pharmaceuticals (NASDAQ:SNOA) has achieved significant regulatory milestones in the United Kingdom, securing MHRA registration for its manufacturing facility and five key products. The approved products include their Microcyn technology-based hypochlorous acid (HOCl) solutions for wound irrigation, scar management, wound hydrogel, and skin exfoliant.

The company, which develops patented Microcyn® technology-based stabilized HOCl products for various applications including wound care, eye, oral, nasal care, dermatological conditions, podiatry, and animal health care, views the UK market as a significant opportunity for expansion, particularly in wound care and dermatology segments.

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, from March 7-11, 2025. The company, which develops Microcyn® technology based stabilized hypochlorous acid (HOCl) products, will showcase its prescription and OTC dermatology products at booth 1054.

The AAD annual meeting is a major dermatology conference featuring over 350 exhibitors, nearly 20,000 attendees including 10,000+ medical personnel, and more than 300 educational sessions. Sonoma aims to expand its distributor network and present its portfolio of products for skin care, scar management, and atopic dermatitis.

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong Q3 fiscal 2025 results with revenues increasing 14% to $3.6 million compared to the prior year. The company achieved positive cash flow from operations, maintaining $5.2 million cash at December 31, 2024.

Key developments include new partnerships with Medline Industries and WellSpring Pharmaceutical to expand U.S. sales, FDA 510(k) clearance for Microcyn technology-based hydrogel, and successful transition to EU Medical Device Regulation for four products. The company relaunched direct sales of prescription dermatology and eye care product lines.

Despite revenue growth, gross margins decreased to 36% from 47% year-over-year due to manufacturing resources allocation for European regulatory requirements. Operating expenses remained flat at $2.3 million, with a quarterly net loss of $0.9 million and EBITDA loss of $1.0 million.

Sonoma Pharmaceuticals (Nasdaq:SNOA) has successfully transitioned four of its products to meet the new European Union Medical Device Regulation (MDR) requirements, achieving Class IIb medical device classification. The products include Microdacyn60® Wound Care, Microdacyn60 Hydrogel, Epicyn® (scar gel), and Pediacyn® for atopic dermatitis.

The EU MDR, adopted in 2017 to replace the Medical Device Directive, requires compliance by December 31, 2028 for non-implantable Class IIb and lower risk devices. The classification was granted after the products met safety and performance requirements and passed conformity assessment, demonstrating their compliance with the new, more stringent European standards.

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the relaunch of its prescription dermatology and eye care product lines in the United States. The company will now directly sell its Microcyn technology-based products, which were previously distributed through a third party. The product lineup includes prescription-strength items like Acuicyn, Epicyn, Levicyn, and Celacyn, along with over-the-counter options Lasercyn Dermal Spray and Gel. These hypochlorous acid-based products will be available from December 9, 2024, with pre-ordering options available.